US Patent

US12324838 — Intranasal epinephrine formulations and methods for the treatment of disease

Formulation · Assigned to Aegis Therapeutics LLC · Expires 2039-02-06 · 13y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects intranasal epinephrine formulations and methods for treating anaphylaxis with epinephrine products.

USPTO Abstract

Drug products adapted for nasal delivery comprising formulations with epinephrine and devices comprising such formulations are provided. Methods of treating anaphylaxis with epinephrine products are also provided.

Drugs covered by this patent

Patent Metadata

Patent number
US12324838
Jurisdiction
US
Classification
Formulation
Expires
2039-02-06
Drug substance claim
No
Drug product claim
Yes
Assignee
Aegis Therapeutics LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.